findmyKOL
Clinical trialNCT04033432UnknownPhase 2Interventional

sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

SponsorNorthwestern UniversityEnrollment14Castration Levels of TestosteroneCastration-Resistant Prostate CarcinomaCastration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted AgentsMetastatic Prostate AdenocarcinomaPSA ProgressionProgressive Disease+4 more conditions
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this phase II, single-arm, open-label, three center study is to evaluate the efficacy, safety, and tolerability of sEphB4-HSA in patients with mCRPC (metastatic castration-resistant prostate cancer). The study drug, sEphB4-HAS, is a form of protein that has not been approved for sale by the United States Food and Drug Administration (FDA). The study drug prevents tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Usc / Norris Comprehensive Cancer Center

    Los Angeles, California, United States

  • Northwestern University

    Chicago, Illinois, United States

  • University of Chicago Comprehensive Cancer Center

    Chicago, Illinois, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

SEphB4-HSA
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
20 Sept 2019
Primary completion
5 Feb 2021
Completion
30 Jun 2022
Last update posted
27 Apr 2022
Registered enrollment
14
Registry id
NCT04033432
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.